NASDAQ:LIFE aTyr Pharma (LIFE) Stock Price, News & Analysis → $16T Crypto Plot From Elon Musk (From Crypto 101 Media) (Ad) Free LIFE Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range$1.57▼$2.0752-Week Range N/AVolume269,400 shsAverage Volume514,103 shsMarket Capitalization$131.12 millionP/E RatioN/ADividend YieldN/APrice Target$23.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get aTyr Pharma alerts: Email Address aTyr Pharma MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside∞ Upside$23.67 Price TargetShort InterestHealthy0.50% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.93Based on 3 Articles This WeekInsider TradingAcquiring Shares$132,650 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.89) to ($0.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.17 out of 5 starsMedical Sector293rd out of 915 stocksBiological Products, Except Diagnostic Industry42nd out of 152 stocks 3.4 Analyst's Opinion Consensus RatingaTyr Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageaTyr Pharma has only been the subject of 1 research reports in the past 90 days.Read more about aTyr Pharma's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.50% of the outstanding shares of aTyr Pharma have been sold short.Short Interest Ratio / Days to CoveraTyr Pharma has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in aTyr Pharma has recently decreased by 46.02%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldaTyr Pharma does not currently pay a dividend.Dividend GrowthaTyr Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LIFE. Previous Next 2.7 News and Social Media Coverage News SentimentaTyr Pharma has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for aTyr Pharma this week, compared to 1 article on an average week.Search Interest5 people have searched for LIFE on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added aTyr Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, aTyr Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $132,650.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.70% of the stock of aTyr Pharma is held by insiders.Percentage Held by Institutions61.72% of the stock of aTyr Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about aTyr Pharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for aTyr Pharma are expected to grow in the coming year, from ($0.89) to ($0.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of aTyr Pharma is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of aTyr Pharma is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about aTyr Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About aTyr Pharma Stock (NASDAQ:LIFE)aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.Read More Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. LIFE Stock News HeadlinesJune 4, 2024 | insidertrades.comSanjay Shukla Purchases 20,000 Shares of aTyr Pharma, Inc. (NASDAQ:LIFE) StockJune 15 at 5:28 AM | americanbankingnews.comaTyr Pharma (NASDAQ:LIFE) Now Covered by Analysts at StockNews.comJune 5, 2024 | investorplace.comMillionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025June 5, 2024 | americanbankingnews.comaTyr Pharma, Inc. (NASDAQ:LIFE) CEO Buys $36,200.00 in StockJune 5, 2024 | americanbankingnews.comaTyr Pharma, Inc. (NASDAQ:LIFE) Director Timothy Coughlin Purchases 50,000 SharesJune 3, 2024 | globenewswire.comaTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”May 25, 2024 | finanznachrichten.deaTyr Pharma, Inc.: aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 24, 2024 | globenewswire.comaTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 15, 2024 | finance.yahoo.comaTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International ConferenceMay 15, 2024 | globenewswire.comaTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International ConferenceMay 14, 2024 | globenewswire.comaTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary SarcoidosisMay 3, 2024 | markets.businessinsider.comStrong Buy Rating for aTyr Pharma as Efzofitimod Shows Promise and Financial StabilityMay 3, 2024 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on aTyr Pharma (LIFE)May 2, 2024 | investorplace.comLIFE Stock Earnings: aTyr Pharma Beats EPS, Beats Revenue for Q1 2024May 2, 2024 | globenewswire.comaTyr Pharma Announces First Quarter 2024 Results and Provides Corporate UpdateApril 21, 2024 | finance.yahoo.comaTyr Pharma Insiders Placed Bullish Bets Worth US$514.6kApril 17, 2024 | msn.comAtal Incubation Centre - Centre for Cellular and Molecular Biology signs agreement with Thermo Fisher Scientific to advance innovation in IndiaApril 1, 2024 | finance.yahoo.comaTyr Pharma to Participate in April Investor ConferencesApril 1, 2024 | globenewswire.comaTyr Pharma to Participate in April Investor ConferencesMarch 26, 2024 | investorplace.com3 Penny Stocks That Could Be Multibaggers in the Making: March EditionMarch 18, 2024 | msn.com3 Best Stocks to Buy Now, 3/18/2024, According to Top AnalystsMarch 17, 2024 | finanznachrichten.deaTyr Pharma, Inc.: aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate UpdateMarch 16, 2024 | benzinga.comRecap: aTyr Pharma Q4 EarningsMarch 16, 2024 | finance.yahoo.comaTyr Pharma Full Year 2023 Earnings: Revenues DisappointMarch 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for aTyr Pharma as Lead Candidate efzofitimod Advances in Clinical Trials with Solid Financial FootingSee More Headlines Receive LIFE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today6/15/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:LIFE CUSIP53217V10 CIK1339970 Webwww.atyrpharma.com Phone(858) 731-8389Fax858-731-8394Employees56Year Founded2005Price Target and Rating Average Stock Price Target$23.67 High Stock Price Target$35.00 Low Stock Price Target$16.00 Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,390,000.00 Net MarginsN/A Pretax Margin-9,172.11% Return on Equity-56.92% Return on Assets-43.87% Debt Debt-to-Equity Ratio0.02 Current Ratio6.07 Quick Ratio6.07 Sales & Book Value Annual Sales$350,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.54 per share Price / BookN/AMiscellaneous Outstanding Shares69,010,000Free Float66,458,000Market Cap$131.12 million OptionableOptionable Beta1.19 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Sanjay S. Shukla M.D. (Age 52)M.S., President, CEO & Director Comp: $768.18kMs. Jill M. Broadfoot (Age 62)Chief Financial Officer Comp: $544.75kMs. Nancy E. Denyes Krueger (Age 56)General Counsel & Corporate Secretary Comp: $518.2kXiang-Lei Yang Ph.D.FounderMs. Ashlee DunstonDirector of Investor Relations & Corporate CommunicationsMr. Peter VilligerVice President of Corporate DevelopmentMs. Danielle CampbellVP of Human ResourceDr. Leslie Nangle Ph.D.Vice President of ResearchDr. Ying J. Buechler Ph.D.Executive Director of Biologics Development & ManufacturingDr. David J. King Ph.D. (Age 65)Scientific Consultant Comp: $327.31kMore ExecutivesKey CompetitorsPacific Biosciences of CaliforniaNASDAQ:PACBHarvard BioscienceNASDAQ:HBIOPTC TherapeuticsNASDAQ:PTCTSarepta TherapeuticsNASDAQ:SRPTThermo Fisher ScientificNYSE:TMOView All CompetitorsInsiders & InstitutionsSanjay ShuklaBought 20,000 shares on 5/31/2024Total: $36,200.00 ($1.81/share)Jill Marie BroadfootBought 5,000 shares on 5/31/2024Total: $8,950.00 ($1.79/share)Timothy CoughlinBought 50,000 shares on 5/30/2024Total: $87,500.00 ($1.75/share)Vanguard Group Inc.Bought 283,703 shares on 5/10/2024Ownership: 3.843%Acadian Asset Management LLCBought 24,704 shares on 5/10/2024Ownership: 0.066%View All Insider TransactionsView All Institutional Transactions LIFE Stock Analysis - Frequently Asked Questions Should I buy or sell aTyr Pharma stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LIFE shares. View LIFE analyst ratings or view top-rated stocks. What is aTyr Pharma's stock price target for 2024? 4 Wall Street analysts have issued 12 month price targets for aTyr Pharma's shares. Their LIFE share price targets range from $16.00 to $35.00. On average, they anticipate the company's stock price to reach $23.67 in the next year. View analysts price targets for LIFE or view top-rated stocks among Wall Street analysts. When is aTyr Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our LIFE earnings forecast. How were aTyr Pharma's earnings last quarter? aTyr Pharma, Inc. (NASDAQ:LIFE) issued its earnings results on Thursday, May, 2nd. The biotechnology company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.01. The biotechnology company had revenue of $0.24 million for the quarter, compared to analysts' expectations of $0.11 million. When did aTyr Pharma's stock split? aTyr Pharma shares reverse split on the morning of Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 28th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What is Sanjay Shukla, M.D, M.S's approval rating as aTyr Pharma's CEO? 3 employees have rated aTyr Pharma Chief Executive Officer Sanjay Shukla, M.D, M.S on Glassdoor.com. Sanjay Shukla, M.D, M.S has an approval rating of 100% among the company's employees. This puts Sanjay Shukla, M.D, M.S in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of aTyr Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other aTyr Pharma investors own include Wynn Resorts (WYNN), Biocept (BIOC), SCYNEXIS (SCYX), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Precigen (PGEN), QUALCOMM (QCOM), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX). When did aTyr Pharma IPO? aTyr Pharma (LIFE) raised $76 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Citigroup acted as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers. Who are aTyr Pharma's major shareholders? aTyr Pharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.84%), GSA Capital Partners LLP (0.33%), Kingswood Wealth Advisors LLC (0.09%), Acadian Asset Management LLC (0.07%) and SG Americas Securities LLC (0.04%). Insiders that own company stock include Jill Marie Broadfoot, Paul Schimmel, Sanjay Shukla and Timothy Coughlin. View institutional ownership trends. How do I buy shares of aTyr Pharma? Shares of LIFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LIFE) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredKiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does ...Porter & Company | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding aTyr Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share aTyr Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.